KCNN4 and amyotrophic lateral sclerosis: Specifically, a pharmacological blockade with KCa3.1 inhibitor, 1- [(2-chlorophenyl)diphenylmethyl]-1H-pyrazole (TRAM-34), has beneficial effects in rodent models of ALS, reducing the expression of inflammatory factors such as TNF-α, Il-1β, Nos2 and increasing anti-inflammatory factors such as arg1, cd163, sosc3, ym1, bdnf and p2yr12 in the spinal cord.